{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:42:39Z","timestamp":1792406559695,"version":"4.4.0"},"reference-count":57,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ck0106274"],"award-info":[{"award-number":["JP17ck0106274"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ck0106546"],"award-info":[{"award-number":["JP20ck0106546"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ama221419"],"award-info":[{"award-number":["JP24ama221419"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ck0106808"],"award-info":[{"award-number":["JP24ck0106808"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JPgm2010009"],"award-info":[{"award-number":["JPgm2010009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP26jf0126022"],"award-info":[{"award-number":["JP26jf0126022"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ck0106065"],"award-info":[{"award-number":["JP25ck0106065"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University"},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004398","name":"Mitsubishi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004398","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project Mirai Cancer Research"},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["25K11172"],"award-info":[{"award-number":["25K11172"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015644","name":"Pancreas Research Foundation of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008673","name":"Yasuda Memorial Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008673","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Gastrointestinal neuroendocrine carcinoma (GIS-NEC) is a highly aggressive malignancy with limited therapeutic options. To identify a therapeutic target, we performed transcriptomic profiling of 34 GIS-NEC and 30 well-differentiated gastrointestinal neuroendocrine tumors (GIS-NET) and found that checkpoint kinase 1 (CHEK1) is significantly overexpressed in GIS-NEC. Although CHEK1 expression was not prognostic across overall GIS-NEC, it was associated with poor outcome specifically in pancreatic NEC, in which it correlated with replication stress\u2013associated genes, including cell division cycle 6 (CDC6) and claspin (CLSPN), both at the intercase level and across spatially distinct regions within individual tumors. Pharmacologic inhibition of checkpoint kinase 1 (CHK1) using prexasertib (LY2606368) suppressed cell proliferation, induced cell-cycle arrest, and increased DNA damage in most GIS-NEC cell lines, recapitulating the effects of CHEK1 knockdown. Antitumor efficacy was further confirmed in vivo. However, pancreatic NEC cell lines exhibited relative resistance to CHK1 inhibition, and transcriptomic analysis revealed enrichment of WNT signaling\u2013related genes in these cells. Low-density lipoprotein receptor\u2013related protein 8 (LRP8) was highly expressed in pancreatic NEC cases with high CHEK1 expression. WNT inhibition suppressed MYC-dependent transcriptional programs and downregulated replication-associated genes, including CDC6, thereby impairing replication capacity. Combined WNT and CHK1 inhibition further exacerbated replication stress and DNA damage, even at low CHK1 inhibitor doses. Collectively, these findings identify CHK1 as a therapeutic vulnerability in GIS-NEC and indicate that WNT\u2013MYC signaling contributes to resistance by sustaining replication programs. Dual targeting of CHK1 and WNT\u2013MYC pathways may therefore represent a promising therapeutic strategy, particularly in pancreatic NEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>CHEK1 is overexpressed in GIS-NEC and represents a therapeutic vulnerability. In tumors in which CHK1 inhibition alone is ineffective, combined CHK1 and WNT inhibition exerts synergistic effects, enhancing replication stress and DNA damage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0351","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:05:42Z","timestamp":1790744742000},"page":"2434-2450","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual CHK1 and WNT Inhibition as a Synergistic Therapy for Gastrointestinal Neuroendocrine Carcinoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-6659","authenticated-orcid":false,"given":"Hirokazu","family":"Kimura","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/035t8zc32","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Osaka 1 Department of Cancer Genome Informatics, Graduate School of Medicine, , Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1614-9028","authenticated-orcid":false,"given":"Yoshihiko","family":"Sato","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/035t8zc32","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Osaka 1 Department of Cancer Genome Informatics, Graduate School of Medicine, , Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-4566","authenticated-orcid":false,"given":"Shinichi","family":"Yachida","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/035t8zc32","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Osaka 1 Department of Cancer Genome Informatics, Graduate School of Medicine, , Osaka, Japan."},{"id":[{"id":"https:\/\/ror.org\/035t8zc32","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Osaka 2 Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), , Osaka, Japan."},{"name":"3Japan Agency for Medical Research and Development -Core Research for Evolutional Science and Technology (AMED-CREST), Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"2026101905560900900_bib1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"2026101905560900900_bib2","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"key":"2026101905560900900_bib3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10555-023-10121-2","article-title":"Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma","volume":"42","author":"Ooki","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"2026101905560900900_bib4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"key":"2026101905560900900_bib5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2026101905560900900_bib6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2026101905560900900_bib7","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/jamaoncol.2022.3395","article-title":"Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial","volume":"8","author":"Morizane","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026101905560900900_bib8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-21-3058","article-title":"Expanding therapeutic opportunities for extrapulmonary neuroendocrine carcinoma","volume":"28","author":"Frizziero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026101905560900900_bib9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jtho.2020.01.016","article-title":"New approaches to SCLC therapy: from the laboratory to the clinic","volume":"15","author":"Poirier","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026101905560900900_bib10","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/cncr.32883","article-title":"Pembrolizumab for the treatment of programmed death\u2013ligand 1\u2013positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","volume":"126","author":"Mehnert","year":"2020","journal-title":"Cancer"},{"key":"2026101905560900900_bib11","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026101905560900900_bib12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br J Cancer"},{"key":"2026101905560900900_bib13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov"},{"key":"2026101905560900900_bib14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2026101905560900900_bib15","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/cas.13078","article-title":"YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer","volume":"107","author":"Horie","year":"2016","journal-title":"Cancer Sci"},{"key":"2026101905560900900_bib16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026101905560900900_bib17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00280-019-03950-y","article-title":"Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development","volume":"85","author":"Angius","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026101905560900900_bib18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2020.09.016","article-title":"Reality CHEK: understanding the biology and clinical potential of CHK1","volume":"497","author":"Neizer-Ashun","year":"2021","journal-title":"Cancer Lett"},{"key":"2026101905560900900_bib19","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/0008-5472.CAN-16-3409","article-title":"CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib","volume":"77","author":"Sen","year":"2017","journal-title":"Cancer Res"},{"key":"2026101905560900900_bib20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cllc.2021.04.005","article-title":"A phase II trial of prexasertib (LY2606368) in patients with extensive-stage small-cell lung cancer","volume":"22","author":"Byers","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2026101905560900900_bib21","doi-asserted-by":"publisher","first-page":"26191","DOI":"10.1038\/srep26191","article-title":"Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing","volume":"6","author":"Cole","year":"2016","journal-title":"Sci Rep"},{"key":"2026101905560900900_bib22","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","article-title":"The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial","volume":"15","author":"Giudice","year":"2024","journal-title":"Nat Commun"},{"key":"2026101905560900900_bib23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/cac2.12372","article-title":"Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract","volume":"42","author":"Wu","year":"2022","journal-title":"Cancer Commun"},{"key":"2026101905560900900_bib24","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1172\/JCI84658","article-title":"CKAP4 is a Dickkopf1 receptor and is involved in tumor progression","volume":"126","author":"Kimura","year":"2016","journal-title":"J Clin Invest"},{"key":"2026101905560900900_bib25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-19-2988","article-title":"E74-like factor 3 is a key regulator of epithelial integrity and immune response genes in biliary tract cancer","volume":"81","author":"Suzuki","year":"2021","journal-title":"Cancer Res"},{"key":"2026101905560900900_bib26","doi-asserted-by":"publisher","first-page":"36503","DOI":"10.18632\/oncotarget.26367","article-title":"Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma","volume":"9","author":"Yanagihara","year":"2018","journal-title":"Oncotarget"},{"key":"2026101905560900900_bib27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/MPA.0b013e3182207a58","article-title":"Establishment and characterization of a new cell line, A99, from a primary small cell carcinoma of the pancreas","volume":"40","author":"Yachida","year":"2011","journal-title":"Pancreas"},{"key":"2026101905560900900_bib28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41418-022-00976-3","article-title":"The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute","volume":"29","author":"de Andrade","year":"2022","journal-title":"Cell Death Differ"},{"key":"2026101905560900900_bib29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","article-title":"The cellosaurus, a cell-line knowledge resource","volume":"29","author":"Bairoch","year":"2018","journal-title":"J Biomol Tech"},{"key":"2026101905560900900_bib30","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1111\/cas.15764","article-title":"An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma","volume":"114","author":"Horie","year":"2023","journal-title":"Cancer Sci"},{"key":"2026101905560900900_bib31","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/s41467-019-11371-x","article-title":"MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer","volume":"10","author":"Dammert","year":"2019","journal-title":"Nat Commun"},{"key":"2026101905560900900_bib32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"ClusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"2026101905560900900_bib33","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2026101905560900900_bib34","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/bioinformatics\/btu033","article-title":"RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies","volume":"30","author":"Stamatakis","year":"2014","journal-title":"Bioinformatics"},{"key":"2026101905560900900_bib35","doi-asserted-by":"publisher","first-page":"e12971","DOI":"10.1111\/jne.12971","article-title":"Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: a population-based study","volume":"33","author":"Abdel-Rahman","year":"2021","journal-title":"J Neuroendocrinol"},{"key":"2026101905560900900_bib36","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1158\/0008-5472.CAN-08-0884","article-title":"Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells","volume":"68","author":"Gali-Muhtasib","year":"2008","journal-title":"Cancer Res"},{"key":"2026101905560900900_bib37","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-12-3748","article-title":"Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776","volume":"19","author":"Engelke","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026101905560900900_bib38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/oncolo\/oyab039","article-title":"Survival according to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas","volume":"27","author":"Dasari","year":"2022","journal-title":"Oncologist"},{"key":"2026101905560900900_bib39","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jtho.2019.01.028","article-title":"Checkpoint kinase 1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in SCLC by promoting mitotic cell death","volume":"14","author":"Hsu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026101905560900900_bib40","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/jso.26644","article-title":"Surgical resection of high-grade nonfunctional pancreatic neuroendocrine carcinoma is associated with improved survival","volume":"124","author":"Jiang","year":"2021","journal-title":"J Surg Oncol"},{"key":"2026101905560900900_bib41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13402-015-0244-6","article-title":"Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible?","volume":"38","author":"Sharan","year":"2015","journal-title":"Cell Oncol"},{"key":"2026101905560900900_bib42","doi-asserted-by":"publisher","first-page":"e59180","DOI":"10.1371\/journal.pone.0059180","article-title":"Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines","volume":"8","author":"Jacob","year":"2013","journal-title":"PLoS One"},{"key":"2026101905560900900_bib43","doi-asserted-by":"publisher","first-page":"110060","DOI":"10.1016\/j.celrep.2021.110060","article-title":"CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment","volume":"37","author":"Klomp","year":"2021","journal-title":"Cell Rep"},{"key":"2026101905560900900_bib44","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"key":"2026101905560900900_bib45","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.18632\/oncotarget.6364","article-title":"A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase","volume":"7","author":"Sakurikar","year":"2016","journal-title":"Oncotarget"},{"key":"2026101905560900900_bib46","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/1878-0261.12882","article-title":"Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation","volume":"15","author":"Zhao","year":"2021","journal-title":"Mol Oncol"},{"key":"2026101905560900900_bib47","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.7150\/thno.96879","article-title":"Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer","volume":"14","author":"Qiu","year":"2024","journal-title":"Theranostics"},{"key":"2026101905560900900_bib48","doi-asserted-by":"publisher","first-page":"146871","DOI":"10.1016\/j.gene.2022.146871","article-title":"WNT6 participates in the occurrence and development of ovarian cancer by upregulating\/activating the typical Wnt pathway and Notch1 signaling pathway","volume":"846","author":"Bao","year":"2022","journal-title":"Gene"},{"key":"2026101905560900900_bib49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/onc.2009.310","article-title":"Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways","volume":"29","author":"Van Amerongen","year":"2010","journal-title":"Oncogene"},{"key":"2026101905560900900_bib50","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","article-title":"Wnt\/\u03b2-catenin signaling in cancers and targeted therapies","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026101905560900900_bib51","doi-asserted-by":"publisher","first-page":"e7930","DOI":"10.1371\/journal.pone.0007930","article-title":"Lrp4, a novel receptor for dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo","volume":"4","author":"Choi","year":"2009","journal-title":"PLoS One"},{"key":"2026101905560900900_bib52","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1080\/21655979.2022.2036917","article-title":"Low-density lipoprotein receptor-related protein 8 facilitates the proliferation and invasion of non-small cell lung cancer cells by regulating the Wnt\/\u03b2-catenin signaling pathway","volume":"13","author":"Fang","year":"2022","journal-title":"Bioengineered"},{"key":"2026101905560900900_bib53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.isci.2019.01.001","article-title":"Tissue-specific Chk1 activation determines apoptosis by regulating the balance of p53 and p21","volume":"12","author":"van Jaarsveld","year":"2019","journal-title":"iScience"},{"key":"2026101905560900900_bib54","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"key":"2026101905560900900_bib55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"2026101905560900900_bib56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat Cell Biol"},{"key":"2026101905560900900_bib57","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s44321-025-00260-0","article-title":"Reelin-LRP8 signaling mediates brain dissemination of breast cancer cells via abluminal migration","volume":"17","author":"Huang","year":"2025","journal-title":"EMBO Mol Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0351\/3834498\/crc-26-0351.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2434\/3840167\/crc-26-0351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2434\/3840167\/crc-26-0351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:56:18Z","timestamp":1792403778000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2434\/789449\/Dual-CHK1-and-WNT-Inhibition-as-a-Synergistic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0351","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34698977","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698965","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698953","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698941","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698983","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698971","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698929","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698917","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698959","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698947","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698935","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698923","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698980","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698944","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698932","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698920","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698974","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698962","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698950","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698938","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698926","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698914","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698968","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34698956","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8782421","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}